These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 21903032)
1. Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging study. Ruhé HG; Booij J; Veltman DJ; Michel MC; Schene AH J Clin Psychiatry; 2012 Apr; 73(4):451-9. PubMed ID: 21903032 [TBL] [Abstract][Full Text] [Related]
2. Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder. Ruhé HG; Koster M; Booij J; van Herk M; Veltman DJ; Schene AH Psychiatry Res; 2014 Feb; 221(2):155-61. PubMed ID: 24406081 [TBL] [Abstract][Full Text] [Related]
3. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Ruhé HG; Booij J; v Weert HC; Reitsma JB; Franssen EJ; Michel MC; Schene AH Neuropsychopharmacology; 2009 Mar; 34(4):999-1010. PubMed ID: 18830236 [TBL] [Abstract][Full Text] [Related]
4. Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine. Fu CH; Costafreda SG; Sankar A; Adams TM; Rasenick MM; Liu P; Donati R; Maglanoc LA; Horton P; Marangell LB BMC Psychiatry; 2015 Apr; 15():82. PubMed ID: 25880400 [TBL] [Abstract][Full Text] [Related]
5. Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Victor TA; Furey ML; Fromm SJ; Ohman A; Drevets WC Arch Gen Psychiatry; 2010 Nov; 67(11):1128-38. PubMed ID: 21041614 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239 [TBL] [Abstract][Full Text] [Related]
8. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Preskorn SH; Baker B; Kolluri S; Menniti FS; Krams M; Landen JW J Clin Psychopharmacol; 2008 Dec; 28(6):631-7. PubMed ID: 19011431 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of mirtazapine as add-on to paroxetine Xiao L; Zhu X; Gillespie A; Feng Y; Zhou J; Chen X; Gao Y; Wang X; Ma X; Gao C; Xie Y; Pan X; Bai Y; Xu X; Wang G; Chen R Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894 [TBL] [Abstract][Full Text] [Related]
10. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial. Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424 [TBL] [Abstract][Full Text] [Related]
11. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Brody AL; Saxena S; Silverman DH; Alborzian S; Fairbanks LA; Phelps ME; Huang SC; Wu HM; Maidment K; Baxter LR Psychiatry Res; 1999 Oct; 91(3):127-39. PubMed ID: 10641577 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial. Yu YM; Gao KR; Yu H; Shen YF; Li HF J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692 [TBL] [Abstract][Full Text] [Related]
13. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Brody AL; Saxena S; Stoessel P; Gillies LA; Fairbanks LA; Alborzian S; Phelps ME; Huang SC; Wu HM; Ho ML; Ho MK; Au SC; Maidment K; Baxter LR Arch Gen Psychiatry; 2001 Jul; 58(7):631-40. PubMed ID: 11448368 [TBL] [Abstract][Full Text] [Related]
14. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Musselman DL; Somerset WI; Guo Y; Manatunga AK; Porter M; Penna S; Lewison B; Goodkin R; Lawson K; Lawson D; Evans DL; Nemeroff CB J Clin Psychiatry; 2006 Feb; 67(2):288-96. PubMed ID: 16566626 [TBL] [Abstract][Full Text] [Related]
15. Changes in the neural correlates of implicit emotional face processing during antidepressant treatment in major depressive disorder. Victor TA; Furey ML; Fromm SJ; Öhman A; Drevets WC Int J Neuropsychopharmacol; 2013 Nov; 16(10):2195-208. PubMed ID: 23809145 [TBL] [Abstract][Full Text] [Related]
17. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Fu CH; Williams SC; Cleare AJ; Brammer MJ; Walsh ND; Kim J; Andrew CM; Pich EM; Williams PM; Reed LJ; Mitterschiffthaler MT; Suckling J; Bullmore ET Arch Gen Psychiatry; 2004 Sep; 61(9):877-89. PubMed ID: 15351766 [TBL] [Abstract][Full Text] [Related]
18. Predicting Treatment Response in Depression: The Role of Anterior Cingulate Cortex. Godlewska BR; Browning M; Norbury R; Igoumenou A; Cowen PJ; Harmer CJ Int J Neuropsychopharmacol; 2018 Nov; 21(11):988-996. PubMed ID: 30124867 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials. Dunner DL; Lipschitz A; Pitts CD; Davies JT Clin Ther; 2005 Dec; 27(12):1901-11. PubMed ID: 16507376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]